BANGKOK LIFE ASSURANCE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.2 THB | -2.27% |
|
-4.44% | -14.00% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its low valuation, with P/E ratio at 9.15 and 7.54 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.00% | 815M | B | ||
| +12.85% | 77.41B | B- | ||
| +8.36% | 50.67B | B+ | ||
| +2.82% | 48.12B | B | ||
| +14.75% | 43.61B | B+ | ||
| +12.52% | 41.74B | B+ | ||
| +5.98% | 30.76B | B | ||
| -2.46% | 29.21B | B- | ||
| -12.42% | 26.1B | A- | ||
| +11.26% | 23.07B | A |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BLA Stock
- Ratings Bangkok Life Assurance